AMOEBA (EPA:AMEBA) - AMOEBA signs a Letter of Intent with MOMAR

Transparency directive : regulatory news

27/07/2017 17:45

PRESS RELEASE

AMOEBA signs a Letter of Intent with MOMAR
For the distribution of BIOMEBA on a new US territory

Lyon (France), Atlanta (GA, USA), July 27th, 2017 - AMOEBA (FR0011051598 -
AMEBA), producer of a biological biocide capable of eliminating bacterial risk
in water, announced today that it has signed a Letter of Intent (LOI) with
MOMAR Inc. prior to entering into a definitive agreement regarding the
distribution of its product in the United States pending marketing
authorization.

The signature of this agreement allows AMOEBA to extend its commercial cover
for the distribution of the green biocide BIOMEBA on the South-East states of
the United States including mainly agri-food and aerospace industries.

"Since MOMAR, Inc. was established in 1947, we have grown continuously through
our industry-leading research and development, our field force with their
problem-solving drive, and by forming partnerships, such as the one we entered
with AMOEBA. Our customers require solutions that provide extensive system
protection options, while maintaining a desire to reduce environmental impact.
MOMAR, Inc. is excited to partner with AMOEBA to bring this new wave of green
technology innovation to our customers, to provide a unique path to control
microbiological growth in their industrial water treatment processes." said
George GRABOW, GENERAL MANAGER of the AquaTrol Division of MOMAR, INC.

"Thanks to the signature of this agreement with MOMAR, we are actively pursuing
our commercial development on the American territory in strengthening our
presence on the southern states of the US which covers a large number of
companies looking for sustainable solutions in industrial water treatment."
stated Fabrice PLASSON, CEO of AMOEBA.

About MOMAR:

Momar, Inc., is a specialty manufacturer of general maintenance and sanitation
chemicals. Founded in Atlanta, Georgia, in 1947, our family-owned and operated
company continues to grow with industry-leading research and advanced product
development. From our original foundation of 150 general and specialized
maintenance chemicals, we have grown to proudly offer over 5,000 MRO
(Maintenance, Repair, and Operations) related products, systems, and services.
Through our Eight Divisions, we specialize as a total fluids manufacturer and
supplier. We provide our customers with virtually every product or service
available in the areas of maintenance chemicals and equipment, lubrication,
water and waste water treatment, food processing chemicals, mineral handling,
dust suppression, specialty hardware, industrial safety equipment, and expert
application services. Our AquaTrol Division is the water treatment division of
Momar. From this Division, we formulate and manufacture a wide variety of
advanced-technology water treatment chemicals and systems for a wide range of
water processing equipment. Our water treatment products protect against
corrosion, scaling, and fouling. They range from potable water corrosion
inhibitors to waste treatment products and solutions. We are committed to
energy efficiency and water savings, offering a full line of
environmentally-responsible products as well as an in-house laboratory for
testing. More information on www.momar.com.

About AMOEBA:

AMOEBA group's objective is to become the global leader in eliminating
waterborne bacterial risk in water treatment and wound care applications. Our
solutions represent alternatives to chemical products widely used in the
cooling water treatment and the wound care market. In a global market for
chemical biocides estimated to be worth EUR 21 bn(1) AMOEBA is focusing on the
industrial cooling tower application estimated at EUR 1.7 bn(2). Similarly, in
a global wound care market estimated at EUR 15.2bn(3), AMOEBA is targeting the
chronic wound care market in the USA, estimated to be worth EUR 751 million(4).
The use of Willaertia magna C2c Maky in health care products will be subject to
FDA (Food and Drug Administration) clearance in the USA. AMOEBA's biological
biocide for water treatment, BIOMEBA, has not yet been granted marketing
authorization in the USA, Europe and Canada. AMOEBA is taking the required
regulatory steps to be granted marketing authorization in those regions for the
use of BIOMEBA in cooling water systems. Based in Chassieu (Lyon, France),
AMOEBA is quoted on compartment C of the Euronext Paris stock exchange and
joined the CAC(r) Small index on 21st September 2015. More information on
www.amoeba-biocide.com.

(1): Sources combined by Amoeba from water treatment agencies, Freedonia,
Eurostat and MarketsandMarkets
(2): Amoeba data combined from the following sources: DRIRE 2013, Eurostat,
ARHIA 2013

Contacts:

Amoéba
Nathalie COMBROUSSE
Marketing Communication Manager
Tel. : +33 (0)4 81 09 18 15
nathalie.combrousse@amoeba-biocide.com

Actifin
Ghislaine GASPARETTO
Financial Communication
Tel. : +33 (0)1 56 88 11 11
ggasparetto@actifin.fr

source : webdisclosure.com

AMOEBA's latest news

07/10/2024 17:45

AMOEBA (EPA:AMEBA) - AMOEBA signs a Letter of Intent with MOMAR

Transparency directive : regulatory news

AMOEBA's latest news

Other stories